Compare DraftKings Inc (DKNG) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DraftKings Inc vs Gilead Sciences, Inc. — how do they compare? DraftKings Inc trades at $25.15 (market cap $12.58B), while Gilead Sciences, Inc. trades at $135.41 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 13.4× DraftKings Inc's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while DraftKings Inc pays none. Which is the better fit depends on your goals.
| DKNG | GILD | |
|---|---|---|
Market Cap | $12.58B | $168.35B |
Sector | Consumer Cyclical | Health |
52-Week High | $48.23 | $155.80 |
52-Week Low | $20.72 | $110.56 |
Enterprise Value | $13.51B | $191.42B |
Dividend Yield | — | 2.42% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
